Protara Therapeutics (TARA) Gains from Sales and Divestitures (2014 - 2025)
Protara Therapeutics (TARA) recorded quarterly Gains from Sales and Divestitures of $130411.0 in Q4 2025, little changed quarter-over-quarter from $130411.0 in Q3 2025, and up 16.88% on a YoY basis from $111579.0 in Q4 2024.
Protara Therapeutics (TARA) Gains from Sales and Divestitures (2014 - 2025) Analysis & Trends
Protara Therapeutics' Gains from Sales and Divestitures history runs 6 years deep, the most recent figure standing at $130411.0 for Q4 2025.
- In Q4 2025, Gains from Sales and Divestitures rose 16.88% year-over-year to $130411.0; the TTM figure through Dec 2025 stood at $130411.0 (up 16.88% YoY), while the FY2025 annual figure was $130411.0, up 16.88% from the prior year.
- Gains from Sales and Divestitures was $130411.0 for Q4 2025 at Protara Therapeutics, roughly flat from $130411.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $188915.0 in Q4 2021 to a low of $30163.0 in Q4 2022.
- Historically, Gains from Sales and Divestitures has averaged $115480.2 across 5 years, with a median of $111579.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Gains from Sales and Divestitures plunged 84.03% in 2022, then jumped 213.39% in 2023.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $188915.0 in 2021, then slumped by 84.03% to $30163.0 in 2022, then surged by 213.39% to $94528.0 in 2023, then advanced by 18.04% to $111579.0 in 2024, then grew by 16.88% to $130411.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $130411.0 (Q4 2025), $130411.0 (Q3 2025), and $130411.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Protara Therapeutics | 216.35 Mn | 216.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 130,411.00 |
| Dec 31, 2025 | 130,411.00 |
| Sep 30, 2025 | 130,411.00 |
| Sep 30, 2025 | 130,411.00 |
| Jun 30, 2025 | 130,411.00 |
| Jun 30, 2025 | 130,411.00 |
| Mar 31, 2025 | 129,203.00 |
| Mar 31, 2025 | 129,203.00 |
| Dec 31, 2024 | 111,579.00 |
| Dec 31, 2024 | 111,579.00 |
| Sep 30, 2024 | 111,579.00 |
| Sep 30, 2024 | 111,579.00 |
| Jun 30, 2024 | 111,579.00 |
| Jun 30, 2024 | 111,579.00 |
| Mar 31, 2024 | 104,484.00 |
| Mar 31, 2024 | 104,484.00 |
| Dec 31, 2023 | 94,528.00 |
| Dec 31, 2023 | 94,528.00 |
| Mar 31, 2023 | 61,444.00 |
| Mar 31, 2023 | 61,444.00 |